Avicena Files Composition Of Matter Patent Application For Treatment Of ALS (Lou Gehrig’s Disease)
Apr 24th 2007Drug InformationBiology
Avicena Group, Inc. (OTC Bulletin Board: AVGOE), a late stage biotechnology company focused on commercializing its proprietary cellular energy modulation technology, announced today that it has filed a composition of matter patent application with the United States Patent and Trademark Office for Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig’s disease), a severe neurodegenerative disease. [click link for full article]
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.